MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:38Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:5-alpha-reductase inhibitors]]
			[[Category:BPH treatments]]
			[[Category:Androgen modulators]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #236

2026-05-23T04:04:20Z

parser-claude batch MedTemplate pre-fill, Top 300 #236

New page

{{MedTemplate
| generic = Dutasteride
| brand = Avodart; combined with tamsulosin as Jalyn
| structure =
| classes = [[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitor (dual type I/II)]], [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]], [[:Category:Androgen_modulators|Androgen modulator]]
| uses = <vote slug="bph-use">Benign prostatic hyperplasia</vote>, <vote slug="androgenetic-alopecia-use">Androgenetic alopecia (off-label, more potent than finasteride)</vote>
| starting_dose = 0.5 mg PO once daily
| preparations = 0.5 mg capsules
| fda_max = 0.5 mg/d
| pill_id =
| routes = Oral
| onset = Prostate volume reduction over 6-12 months
| duration = 24 hours; tissue effects persist weeks
| halflife = ~5 weeks (much longer than finasteride's ~6 hours)<ref name="avodart-label">FDA Prescribing Information, Avodart (dutasteride), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020180s045lbl.pdf</ref>
| bioavailability = ~60% (oral)<ref name="avodart-label" />
| pregnancy = '''Pregnant individuals should not handle dutasteride capsules''' (skin absorption risk through intact capsule); can cause hypospadias in male fetus.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="dutasteride-mech-claim">Dutasteride inhibits both type I (skin, hepatic) and type II (prostatic) 5α-reductase, achieving >90% serum DHT suppression compared with finasteride's ~70%; the dual inhibition translates to greater prostate volume reduction but a similar overall clinical effect in BPH.</vote> The long half-life means blood donation should be deferred for 6 months after the last dose (per FDA labeling) to prevent fetal exposure in a pregnant transfusion recipient. Post-finasteride/dutasteride syndrome (persistent sexual and mood effects after discontinuation) is a controversial but recognized clinical concern<ref name="avodart-label" />.
}}

== References ==
<references />

Dutasteride - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #236